High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: A population-based analysis

Thenappan Chandrasekar, Zachary Klaassen, Hanan Goldberg, Rashid K. Sayyid, Girish S. Kulkarni, Neil E. Fleshner

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Fingerprint

Dive into the research topics of 'High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: A population-based analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences